Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-04T18:08:41.775Z Has data issue: false hasContentIssue false

Parvovirus vectors: use and optimisation in cancer gene therapy

Published online by Cambridge University Press:  23 July 2004

Boris Blechacz
Affiliation:
Molecular Medicine Program, Mayo Clinic, 200 First Street SW, Guggenheim 18-33, Rochester, MN 55905, USA.
Stephen J. Russell
Affiliation:
Molecular Medicine Program, Mayo Clinic, 200 First Street SW, Guggenheim 18-33, Rochester, MN 55905, USA.

Abstract

With the increasing incidence and mortality of cancer worldwide, there is an urgent need for new therapeutic approaches. Gene therapy is one such approach and preliminary data are promising. Viral and nonviral vector systems for gene delivery are available, but most of the current systems suffer from disadvantages such as low transfection efficiencies, in vivo instability, targeting problems, mutagenic potential and immunogenicity. Viruses of the Parvoviridae family, which are characterised by their oncotropism, oncosuppression, long-term gene expression and human apathogenicity, potentially offer advantages as viral vectors. This article evaluates their usefulness in gene therapy strategies for cancer.

Type
Review Article
Copyright
© Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)